secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2021-08-11T23:59:59+00:00
Accession:  0001558370-21-011226
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx Q2 net loss $20.1M ($0.46/sh); cash runway into Q2 2023
----------------------------------------------------------------

- Net loss attributable to shareholders $20.1M ($0.46/sh) vs $25.4M ($0.69/sh) in Q2 2020.
- License revenue $5.1M (up from $2.5M); R&D spend $15.2M, G&A $10.4M.
- Cash and equivalents $172.6M (down from $194.8M); believes funded into Q2 2023.
- Expects to initiate Phase 3 Lumeos trial for XLRP, Phase 3 for AAV-RPE65, and file IND for AAV-GAD in Parkinsons in H2 2021.
- Manufacturing facility to support at least six clinical programs in next 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837021011226/0001558370-21-011226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837021011226/mgtx-20210811x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-011226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer